EXHIBIT 99.02
Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com | ![]() |
Press Release |
Notification of major interests in shares
Basingstoke, UK and Philadelphia, US – June 18, 2008 – Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
Shire Limited
2. Reason for the notification | State Yes/No |
An acquisition or disposal of voting rights | Yes |
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | |
An event changing the breakdown of voting rights | |
Other (please specify): New Exemption DTR 5.1.3 (4) & DTR 5.1.5 (1) | Yes |
3. Full name of person(s) subject to the notification obligation: | The Goldman Sachs Group Inc |
4. Full name of shareholder(s) (if different from 3.): | Goldman, Sachs & Co., Goldman Sachs Financial Markets, L.L.C. Goldman Sachs Execution and Clearing, L.P |
5. Date of the transaction (and date on which the threshold is crossed or reached if different): | 16 June 2008 |
6. Date on which issuer notified: | 18 June 2008 |
7. Threshold(s) that is/are crossed or reached: | Below 3% |
8. Notified details: |
1
A: Voting rights attached to shares
Class/type of shares if possible using the ISIN CODE | Situation previous to the Triggering transaction | Resulting situation after the triggering transaction | |||||
Number of Shares | Number of Voting Rights | Number of shares | Number of voting rights | % of voting rights | |||
Direct | Direct | Indirect | Direct | Indirect | |||
GB00B0KQX869 US82481R1068 | 115,000 17,114,532 (5,704,844 ADRs) | 0.021% 3.059% |
B: Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument | Expiration date | Exercise/Conversion Period/ Date | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights |
Total (A+B) | |
Number of voting rights | % of voting rights |
Below 3% |
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:
We hereby notify you that as at close of business on 16 June 2008, The Goldman Sachs Group, Inc., of 85 Broad Street, New York, NY 10004, USA, no longer has a notifiable interest in shares. |
Proxy Voting:
10. Name of the proxy holder: | N/A |
11. Number of voting rights proxy holder will cease to hold: | N/A |
12. Date on which proxy holder will cease to hold voting rights: | N/A |
13. Additional information: | General Email Contact: shareholderdisclosures@gs.com |
14. Contact name: | Sean Rogers/Alan Cox |
15. Contact telephone number: | 0207-552-9205 / 0207-774 -8774 |
Contact at Shire Limited: Tony Guthrie, Deputy Company Secretary, 01256 894746
2
For further information please contact:
Investor Relations | Cléa Rosenfeld (Rest of the World) | +44 1256 894 160 |
Eric Rojas (North America) | +1 484 595 8252 | |
Media | Jessica Mann (Rest of the World) | +44 1256 894 280 |
Matthew Cabrey (North America) | +1 484 595 8248 | |
Jessica Cotrone (North America) | +1 617 613 4640 |
Notes to editors
SHIRE LIMITED
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.
3